Compare AWP & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWP | ABEO |
|---|---|---|
| Founded | 2007 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.7M | 280.2M |
| IPO Year | 2007 | 2005 |
| Metric | AWP | ABEO |
|---|---|---|
| Price | $12.00 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 159.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | ★ N/A | $5.01 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $3.67 | $4.00 |
| 52 Week High | $12.71 | $7.54 |
| Indicator | AWP | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 58.86 |
| Support Level | $11.48 | $4.87 |
| Resistance Level | $12.00 | $5.30 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 93.38 | 82.35 |
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.